Halozyme Therapeutics

Recent news

• Halozyme Therapeutics(HALO.US) Officer Sells US$6.28 Million in Common Stock
  Market Newswire · 2026/8/20
• Rating change
  TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96
  Market Newswire · 2026/5/12
• Rating change
  Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75
  Market Newswire · 2026/6/15
• Company notice
  Halo Xin.com: Prompt Announcement on Disclosing the Report for the Third Quarter of 2023
  SZSI · 2023/10/24
• Rating change
  China Resources Land Life (1209.HK): A leading operator of consumer‑focused HALO assets in China.
  Huatai Securities · 2026/5/15
• Analysts' Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)
  TipRanks · 2026/9/3
• Rating change
  H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95
  Market Newswire · 2026/7/22
• Company notice
  Halo Technologies Holdings Ltd: HALO to issue Convertible Notes to raise up to AUD6.75m
  N/A · 2024/8/29
• Company notice
  Better Choice Co | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-HEP Partners LLC(7.5%),HH-Halo GP LLC(7.5%), etc.
  SEC · 2024/2/15
• Rating change
  J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
  TipRanks · 2026/5/20
• Company notice
  Akanda | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Halo Collective Inc.(0%)
  SEC · 2024/2/21
• Form 144 | Halozyme Therapeutics(HALO.US) Director Proposes to Sell 3.64 Million in Common Stocks
  Market Newswire · 2026/9/17
• Company notice
  RIMBACO: JOINT ANNOUNCEMENT1. CLOSE OF MANDATORY UNCONDITIONAL CASH OFFER BY CMB INTERNATIONAL CAPITAL LIMITED AND CEB INTERNATIONAL CAPITAL CORPORATION LIMITED FOR AND ON BEHALF OF AUREOLE HALO LIMITED TO ACQUIRE ALL THE ISSUED SHARES OF RIMBACO GROUP GLOBAL LIMIT
  HKEX · 2026/7/7
• Rating change
  Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57
  Market Newswire · 2026/6/15
• Rating change
  Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41
  Market Newswire · 2026/5/12
• Rating change
  Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $93
  Market Newswire · 2026/5/12
• Rating change
  A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $93 to $115
  Market Newswire · 2026/8/8
• Rating change
  Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93
  Market Newswire · 2026/6/15
• H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115
  Market Newswire · 2026/9/3
• Halozyme Therapeutics(HALO.US) Officer Sells US$6.44 Million in Common Stock
  Market Newswire · 2026/9/12

Headlines are aggregated automatically and are not independently verified or edited by our team.